Angiotensin-Converting Enzyme 2: The First Decade
The renin-angiotensin system (RAS) is a critical regulator of hypertension, primarily through the actions of the vasoactive peptide Ang II, which is generated by the action of angiotensin-converting enzyme (ACE) mediating an...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2012/307315 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552707484811264 |
|---|---|
| author | Nicola E. Clarke Anthony J. Turner |
| author_facet | Nicola E. Clarke Anthony J. Turner |
| author_sort | Nicola E. Clarke |
| collection | DOAJ |
| description | The
renin-angiotensin system (RAS) is a critical
regulator of hypertension, primarily through the
actions of the vasoactive peptide Ang II, which
is generated by the action of angiotensin-converting enzyme (ACE) mediating an increase in
blood pressure. The discovery of ACE2, which
primarily metabolises Ang II into the
vasodilatory Ang-(1-7), has added a new
dimension to the traditional RAS. As a result
there has been huge interest in ACE2 over the
past decade as a potential therapeutic for
lowering blood pressure, especially elevation
resulting from excess Ang II. Studies focusing
on ACE2 have helped to reveal other actions of
Ang-(1-7), outside vasodilation, such as
antifibrotic and antiproliferative effects.
Moreover, investigations focusing on ACE2 have
revealed a variety of roles not just catalytic
but also as a viral receptor and amino acid
transporter. This paper focuses on what is
known about ACE2 and its biological roles,
paying particular attention to the regulation of
ACE2 expression. In light of the entrance of
human recombinant ACE2 into clinical trials, we
discuss the potential use of ACE2 as a
therapeutic and highlight some pertinent
questions that still remain unanswered about
ACE2. |
| format | Article |
| id | doaj-art-57e4575b834b42058b161698675780c2 |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-57e4575b834b42058b161698675780c22025-02-03T05:57:58ZengWileyInternational Journal of Hypertension2090-03842090-03922012-01-01201210.1155/2012/307315307315Angiotensin-Converting Enzyme 2: The First DecadeNicola E. Clarke0Anthony J. Turner1Institute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UKInstitute of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UKThe renin-angiotensin system (RAS) is a critical regulator of hypertension, primarily through the actions of the vasoactive peptide Ang II, which is generated by the action of angiotensin-converting enzyme (ACE) mediating an increase in blood pressure. The discovery of ACE2, which primarily metabolises Ang II into the vasodilatory Ang-(1-7), has added a new dimension to the traditional RAS. As a result there has been huge interest in ACE2 over the past decade as a potential therapeutic for lowering blood pressure, especially elevation resulting from excess Ang II. Studies focusing on ACE2 have helped to reveal other actions of Ang-(1-7), outside vasodilation, such as antifibrotic and antiproliferative effects. Moreover, investigations focusing on ACE2 have revealed a variety of roles not just catalytic but also as a viral receptor and amino acid transporter. This paper focuses on what is known about ACE2 and its biological roles, paying particular attention to the regulation of ACE2 expression. In light of the entrance of human recombinant ACE2 into clinical trials, we discuss the potential use of ACE2 as a therapeutic and highlight some pertinent questions that still remain unanswered about ACE2.http://dx.doi.org/10.1155/2012/307315 |
| spellingShingle | Nicola E. Clarke Anthony J. Turner Angiotensin-Converting Enzyme 2: The First Decade International Journal of Hypertension |
| title | Angiotensin-Converting Enzyme 2: The First Decade |
| title_full | Angiotensin-Converting Enzyme 2: The First Decade |
| title_fullStr | Angiotensin-Converting Enzyme 2: The First Decade |
| title_full_unstemmed | Angiotensin-Converting Enzyme 2: The First Decade |
| title_short | Angiotensin-Converting Enzyme 2: The First Decade |
| title_sort | angiotensin converting enzyme 2 the first decade |
| url | http://dx.doi.org/10.1155/2012/307315 |
| work_keys_str_mv | AT nicolaeclarke angiotensinconvertingenzyme2thefirstdecade AT anthonyjturner angiotensinconvertingenzyme2thefirstdecade |